Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryJun052014	Fate Therapeutics to Highlight Potential Clinical Applications of Ex Vivo Hematopoietic Cell Modulation at 12th International Cord Blood Symposium SAN DIEGO, June 5, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that potential clinical applications of its ex vivo approach to Read All »	View HTML Fate Therapeutics to Highlight Potential Clinical Applications of Ex Vivo Hematopoietic Cell Modulation at 12th International Cord Blood Symposium 16.7 KB
Toggle SummaryJun162016	Fate Therapeutics to Host Off-the-Shelf Cancer Immunotherapy Focus Session at 2016 Annual Meeting of International Society for Stem Cell Research SAN DIEGO, June 16, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it will host a Focus Session entitled " Fighting Cancer with Read All »	View HTML Fate Therapeutics to Host Off-the-Shelf Cancer Immunotherapy Focus Session at 2016 Annual Meeting of International Society for Stem Cell Research 19.5 KB
Toggle SummaryNov302020	Fate Therapeutics to Host Virtual Event at the 2020 ASH Annual Meeting SAN DIEGO , Nov. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that management will host a virtual event entitled “ Read All »	View HTML
Toggle SummaryDec082021	Fate Therapeutics to Host Virtual Event at the 2021 ASH Annual Meeting SAN DIEGO , Dec. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that management will host a virtual event entitled “B -cell Read All »	View HTML
Toggle SummaryJul162021	Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma SAN DIEGO , July 16, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that management will host a virtual event to highlight interim Phase 1 Read All »	View HTML
Toggle SummaryApr272017	Fate Therapeutics to Kick-Off 2017 Annual Meeting of International Society for Stem Cell Research with Off-the-Shelf Natural Killer Cell Cancer Immunotherapy Focus Session New Preclinical Data to be Presented on First-of-Kind Product Candidates Derived from Master Engineered Pluripotent Cell Lines Read All »	View HTML Fate Therapeutics to Kick-Off 2017 Annual Meeting of International Society for Stem Cell Research with Off-the-Shelf Natural Killer Cell Cancer Immunotherapy Focus Session 20.1 KB
Toggle SummarySep022022	Fate Therapeutics to Participate at Upcoming September Investor Conferences SAN DIEGO , Sept. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company Read All »	View HTML
Toggle SummaryApr082015	Fate Therapeutics to Present at 14th Annual Needham Healthcare Conference SAN DIEGO, April 8, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President and Read All »	View HTML Fate Therapeutics to Present at 14th Annual Needham Healthcare Conference 10.5 KB
Toggle SummaryFeb072013	Fate Therapeutics to Present at 15th Annual BIO CEO & Investor Conference SAN DIEGO, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, today announced that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will be presenting a company overview Read All »	View HTML Fate Therapeutics to Present at 15th Annual BIO CEO & Investor Conference 9.8 KB
Toggle SummaryAug292019	Fate Therapeutics to Present at 2019 Wells Fargo Healthcare Conference SAN DIEGO , Aug. 29, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko , President and Chief Executive Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.